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Non-invasive delivery of biotherapeutics, as an attractive alternative to injections, could potentially be achieved
through the mucosal surfaces, utilizing nanoscale therapeutic carriers. However, nanoparticles do not readily
cross themucosal barriers, with the epithelium presenting amajor barrier to their translocation. The transcytotic
pathway of vitamin B12 has previously been shown to ‘ferry’ B12-decorated nanoparticles across intestinal epithelial
(Caco-2) cells. However, such studies have not been reported for the airway epithelium. Furthermore, the presence
in the airways of the cell machinery responsible for transepithelial trafﬁcking of B12 is not widely reported. Using a
combination of molecular biology and immunostaining techniques, our work demonstrates that the bronchial cell
line, Calu-3, expresses the B12-intrinsic factor receptor, the transcobalamin II receptor and the transcobalamin II car-
rier protein. Importantly, the work showed that sub-200 nm model nanoparticles chemically conjugated to B12
were internalised and transported across the Calu-3 cell layers, with B12 conjugation not only enhancing cell uptake
and transepithelial transport, but also inﬂuencing intracellular trafﬁcking. Ourwork therefore demonstrates that the
B12 endocytotic apparatus is not only present in this airway model, but also transports ligand-conjugated
nanoparticles across polarised epithelial cells, indicating potential for B12-mediated delivery of nanoscale carriers
of biotherapeutics across the airways.
© 2013 The Authors. Published by Elsevier B.V. All rights reserved.
1. Introduction
Considering the recent emergence of biotherapeutics, developments
in non-invasive delivery options for this class ofmedicines have been dis-
appointing, with the parenteral method remaining the predominant
administration route. Non-invasive administration via the mucosal
surfaces (e.g. gut or airway epithelia) is highly desirable, but at the same
time a formidable task, primarily due to the poor absorption of
biomacromolecules across the mucosae. Mucosal absorption of biomole-
cules could potentially be improved by inducing reversible ‘opening’ of
the epithelial tight junctions, creating a temporarily accessible corridor
for the therapeutic to traverse the epithelial barrier [1–3]. This strategy
however may be limited to relatively small biomolecules (peptides
or small proteins), whilst systemic delivery of larger biotherapeutics
(e.g. antibodies or PEGylated antibody fragments) through this approach
is shown to be inefﬁcient [4]. Furthermore, the longer-term implications
of repeated opening of the tight junctions are currently unclear. Mucosal
absorption of the therapeutic via transport through the epithelial cells (i.e.
the transcellular route) would potentially overcome this problem.
A number of biological transport pathways operate at mucosal
surfaces, ‘shuttling’ various molecules including nutrients (e.g. vitamin
B12 [5]) and endogenous macromolecules (e.g. albumin and IgG [6])
across the epithelium. These physiological pathways could potentially
be exploited for transmucosal delivery of biomolecules, delivered
encapsulated within appropriately decorated nanoparticulate carriers
[7,8].
The present work investigated whether the vitamin B12 (herein
referred to ‘B12’) pathway could carry decorated nanoparticles across
the airway mucosa. The B12 transcytotic pathway has demonstrated
potential for intestinal delivery of peptides and proteins [7,9–12] and
its presence has been conﬁrmed in intestinal cell lines, Caco-2 [13,14]
and HT29 [15,16]. Importantly, the B12 pathway has also been shown
to transport nanoparticles across intestinal Caco-2 cells [11,17,18].
Whilst the possibility of targeting the B12 transcytosis pathway for
delivery of biotherapeutics and nanocarriers has been demonstrated
in the intestinal epithelium, information on the presence and its func-
tioning in the pulmonary system is sparse [19] and knowledge on the
drug delivery potential of this epithelial transport route in the airway
epithelium is currently not available.
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Here we demonstrate the expression and functioning of the B12
transcytotic system in differentiated, polarised culture of bronchial
Calu-3 cells, and extend this to probing whether this pathway can be
exploited for transairwaydelivery of nanoparticles asmodel therapeutic
carriers. The objective of this work stems from other published studies
by our group, which showed folate receptor expression and its endocy-
totic activity in airway epithelial cells [20,21]. Initial experiments
assessed the expression of relevant pathway components: intrinsic
factor (IF)-B12 receptor (‘cubilin’), the transcobalamin II receptor (‘TCII
receptor’) and transcobalamin II carrier protein (‘TCII protein’), the
latter being responsible for the delivery of B12 out of the basolateralmem-
brane of epithelial cells in vivo. We further show cellular internalisation
and transepithelial transport of B12-conjugated nanoparticles and unravel
the endocytic mechanisms involved in the trafﬁcking of B12-decorated
nanoparticles.
2. Materials and methods
Solid 1,1′-carbonyldiimidazole (CDI), anhydrous dimethyl sulf-
oxide, cyanocobalamin and N-hydroxy-succinimide (NHS) were
purchased from Acros® (Belgium). 1-Ethyl-3-[3-dimethylaminopropyl]
carbodiimide (EDAC) was obtained from Calbiochem® (UK). Unless
otherwise stated, all other chemicals and materials were supplied by
Sigma-Aldrich® (UK) or Fisher Scientiﬁc® (UK).
2.1. Preparation of the α-ω-aminohexylcarbamate derivative
of cyanocobalamin
The α-ω-aminohexylcarbamate derivative of cyanocobalamin
was prepared using a method described previously [18]. Brieﬂy,
solid CDI (260 mg, 0.32 mmol) was added to cyanocobalamin
(1.0 g, 0.148 mmol) previously dissolved in anhydrous dimethyl sulf-
oxide. Themixturewas stirred for up to 2 h at 30 °C, followed by the ad-
dition of dry 1,6-hexanediamine (314 mg, 0.54 mmol) and stirring of
the mixture at room temperature over 24 h. The mixture was poured
into ethyl acetate (30 ml) and left to stand. Following centrifugation
and decanting of the supernatant, the residue was sonicated for 5 min
in acetone (50 ml). The resulting precipitate was ﬁltered and the solid
washed in acetone. The crude product was puriﬁed by silica column
chromatography (45% v/v 2-propanol, 30% v/v n-butanol, 2% v/v ammo-
nia and 25% v/v water) followed by lyophilisation.
2.2. Preparation of B12-conjugated nanoparticles
1 ml of ﬂuorescent carboxylate Yellow Orange (YO, ﬂuorescence
spectra equivalent to rhodamine) polystyrene nanoparticles of 50 nm,
and 100 nm (2.69 and 2.6% w/v aqueous suspension, respectively;
PolySciences Inc., Germany) were modiﬁed with the α-ω-
aminohexylcarbamate B12 derivative (10 mg) by activation with
1-ethyl-3-[3-dimethylaminopropyl]carbodiimide (EDAC), in the
presence of N-hydroxy-succinimide (NHS). The reaction was allowed
to proceed for 5 h followed by incubation with glycine (100 mg/ml)
in 50 mM carbonate buffer, pH 9.5, to block residual activated carboxyl
sites. The particles were then dialyzed extensively against distilled
water over 24 h, whilst exchanging the water at regular intervals.
2.3. Characterisation of B12-conjugated nanoparticles
Extensive characterization of the B12 derivative and the conjugated
nanoparticles (e.g. size and surface charge determination pre- and
post-B12 conjugation) was described in a recent publication by our
group [18].
2.4. Cell culture
Calu-3 cells (American Type Culture Collection, USA) were cul-
tured using Eagle's Minimum Essential Medium (LGC standards,
UK), supplemented with penicillin (100 units/ml), streptomycin
(0.1 mg/ml), amphotericin (0.25 μg/ml) and Foetal Bovine Serum
(FBS, 10% v/v). Cells were seeded on Transwell® inserts (12 mm di-
ameter, 0.4 μmpore size; Corning Life Sciences, Holland) at 105 cells/cm2
and cultured for 14–21 days, withmedium replacement every other day.
Calu-3 cells were cultured using air-interfaced culture (AIC) conditions
(known to promote mucus secretion), which were created on day 2
post-seeding on ﬁlter supports. Cell conﬂuence and cell layer integrity
following nanoparticle exposure were conﬁrmed by transepithelial elec-
trical resistance measurements (TEER) using an EVOM (World Precision
Elements, USA) voltohmmeter. TEER post-nanoparticle incubation did
not drop signiﬁcantly (Supporting information, Fig. S1), suggesting no
effect on the integrity of the cell layers.
2.5. mRNA expression of cubilin and TCII receptor in Calu-3 cells
2.5.1. mRNA isolation and cDNA synthesis
The μMACS™ (Miltenyi Biotec, UK) was used to extract mRNA and
synthesise cDNA from Calu-3 cells and Caco-2 cells (used as a control)
cultured on Transwell® supports for 21 days. This single-step technique
that captures mRNA magnetically with oligo-dT magnetic beads was
conducted according to the manufacturer's recommended protocol.
Note, that 50 μl of sscDNA was collected per tube of which 20 μl was
collected and pooled for primer optimisation.
2.5.2. Primer design
The ensemble database was consulted for primer design (www.
ensembl.org). PCR primers for human cubilin (HsCUBN_FOR): 5′-
TCCGGCAGACATTGGGGCCT-3′ and (HsCUBN_REV): 5′-TCCGTGAC
CCTGCGGTGAGT-3′ were designed from human cubilin sequence,
National Center for Biotechnology Information (NCBI) Reference
Sequence NM_001081.3. PCR primers for human TCII receptor
(CD320) (HsCD320_FOR): 5′-CACCCACCAAGTTCCAGTGCCG-3′ and
(HsCD320_REV): 5′-GTTCCACAGCCGAGCTCGTCG-3′ were designed
from human CD320 sequence, NCBI Reference Sequence NM_016579.3.
Primers for cubilin span an exon–exon junction with an intron size of
18,192 basepairs (forward primer) and 3947 basepairs (reverse primer).
The primers for CD320 include an intronwith a size of 942 bp. Both prim-
er pairs were blasted against the human genome (Primer-Blast on NCBI
Blast) and identiﬁed one single amplicon of the correct size in each case.
2.5.3. Polymerase chain reaction (PCR)
Standard PCR ready-to-use Master Mix (REDTaq® ReadyMix™ PCR
Reaction Mix, Sigma-Aldrich, UK) was used to prepare the PCR reaction
mixture. The ﬁnal reaction mixture consisted of 10 μl PCR Master-Mix,
1 μl each of forward and reverse primers for the gene of interest
(5 μM each ﬁnal concentration), 1 μl DNA template (extracted cDNA of
ﬁlter-cultured Calu-3 and Caco-2 cells) and 7 μl nuclease free water
(Roche, UK),making aﬁnal volumeof 20 μl permicrotube. PCR ampliﬁca-
tion of cDNA for human cubilin was performed using the following
sequential cycles: initial heating at 94 °C for 5 min, 94 °C for 30 s,
annealing at 60 °C for 45 s, extension at 72 °C for 90 s, and this cycling re-
peated 34 times, followedby aﬁnal extension at 72 °C for 5 min to ensure
completion of all strands. A similar PCR programme was followed for
human TCII receptor but with denaturation steps at 58 °C. Reactions
were carried out in a PTC-200 Peltier Thermal Cycler (MJ Research, UK).
The reaction mixes were incubated at 4 °C prior to DNA agarose gel
electrophoresis.
2.5.4. DNA agarose gel electrophoresis
The PCR products of 602 bp and 343 bp for cubilin and TCII receptor,
respectively, were analysed by DNA Agarose gel electrophoresis.
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Agarose gels were prepared using a well-established protocol, devel-
oped by the group and adapted from Sambrook and Russell [22]. Brieﬂy,
1% (w/v) agarose gels were prepared using analytical grade agarose
(Promega, UK) in 0.5X TBE buffer (1 M Tris–HCl; 1 M Boric Acid;
0.05 M EDTA; pH 8.0) with the addition of ethidium bromide
(10 μg/ml). 8 μl (0.8 μg) of TriDye 100 bp DNA Ladder was loaded per
gel lane (2 lanes per gel on either side of DNA samples). The DNA sam-
ples were loaded (15–20 μl per gel lane) and the gels were run in 0.5X
Tris/Borate/EDTA (TBE) buffer and electrophoresis was performed
using a horizontal gel apparatus (Fisher Scientiﬁc, UK) at 100–110 V.
DNA fragments were visualised on a UV transilluminator with Gene
Genius Bio imaging software (UVP, USA).
2.6. Immunostaining for cubilin, transcobalamin II receptor and
transcobalamin II protein
Following culture as polarised layers, Calu-3 cells were ﬁxed using
4% w/v paraformaldehyde (in PBS) for 10 min at room temperature.
Cells were then washed with PBS, followed by incubation with 1% w/v
BSA in PBS for 1 h. The cells were then subjected to 30 min incubation
with rabbit, anti-human cubilin H-300 (Santa Cruz Biotechnology,
Inc.), rabbit, anti-human CD320 (TCII receptor, Abcam) or rabbit
transcobalamin II H-260 (Santa Cruz Biotechnology, Inc.), all diluted
1:50 with 1% w/v BSA/PBS. The cells were then washed extensively
with PBS and incubated with the secondary antibodies (chicken anti-
rabbit Alexa-Fluor 488 for TCII receptor, and goat, anti-rabbit IgG-
rhodamine, for cubilin and TCII), diluted 1:100 (in 1% w/v BSA/PBS)
for another 30 min. In the control experiment cell layerswere incubated
with the secondary antibodies only. Following a ﬁnal wash step, cell
nuclei were stained with Hoechst 33342 (0.1 mg/ml), the cells washed
and the ﬁlter membrane excised. Cells were mounted on a slide using
1,4-diazabicyclo[2.2.2]octane (DABCO) (1% diluted in 9:1 glycerol:PBS)
and covered with a glass cover slip. Confocal imaging was carried
out using a Leica SP2 CLSM-Micro4 confocal microscope (Leica,
Germany).
2.7. Cellular uptake and transport studies of B12-conjugated nanoparticles
Culture medium was removed from ﬁlter-cultured Calu-3 cells
(cultured using AIC conditions) and replaced with Hank's Balanced
Salt Solution (HBSS), buffered with 2-[4-(2-hydroxyethyl)piperazin-1-
yl]ethanesulfonic acid (HEPES, 20 mM); cell layers were incubated
with HBSS for 45 min. Unmodiﬁed YO nanoparticles (50, 100 nm) and
B12-conjugated nanoparticles were suspended in HBSS/HEPES to
achieve a ﬁnal concentration of 400 μg/ml. Approximately 0.115 μg of
recombinant human intrinsic factor (rHUIF, Autogen Bioclear Ltd) was
added per 1 ng of B12 and the solution was incubated at 37 °C prior to
application to cells. Following a routinemeasurement of TEER (to assess
cell layer integrity and hence their suitability for inclusion in the exper-
iments) nanoparticle suspensions (0.5 ml) were applied to the apical
chamber of quadruplicate wells and the Calu-3 cultures incubated at
37 °C over 3 h. B12-conjugated nanoparticles were also applied to the
cells in the absence of IF. At 30 minute sampling intervals, 100 μl was
removed from the basolateral side and analysed for ﬂuorescence.
Sample losses were replaced with 100 μl of HEPES/HBSS to maintain
the basolateral volume constant. Internalised ﬂuorescence (indicating
nanoparticle uptake) was determined by cell lysis using 0.2% Triton
X-100 (Fluka) (10 min incubation). Cell uptake of nanoparticles was
quantiﬁed by ﬂuorescence (Dynex, microplate reader, 529 nm/546 nm)
using calibration curves (conducted in triplicates, in themedium replicat-
ing the experimental conditions). Soluble B12 transport studies were
conducted in a similar manner to nanoparticle transport experiments,
with B12 quantiﬁed by UV (350 nm, Beckman Coulter DU 800 UV
spectrophotometer).
2.8. Immunostaining for clathrin and caveolin-1
For immunostaining experiments, culture medium was removed
and cells incubated with HBSS for 45 min. The cell monolayers were
then ﬁxed with 4% paraformaldehyde (diluted in PBS) for 10 min at
room temperature. For these studies, an additional permeabilization
step was conducted via the addition of 0.2% Triton X-100 for 10 min.
The cells were washed with PBS, before incubation with 1% BSA/PBS
(for 1 h). The primary antibody for caveolin-1 (rabbit, anti-human
caveolin-1 H-97 IgG; Santa Cruz Biotechnology, Inc., USA) was diluted
1:50 with 1% BSA/PBS and incubated with the cells for 30 min. For
clathrin immunostaining, rabbit, anti-human clathrin IgG (Abcam®,
UK) was diluted 1:200 in 1% BSA/PBS. The cells were washed 3 times
with PBS and incubated with the secondary antibody (goat, anti-rabbit
IgG-rhodamine and goat, anti-rabbit IgG-FITC for caveolin-1 and
clathrin, respectively) diluted 1:100 (in 1% BSA/PBS) for another
30 min. The control cell layerswere incubatedwith the appropriate sec-
ondary antibody only. Following a ﬁnal wash step, the cell nuclei were
stainedwithHoechst 33342 (0.1 mg/ml), the cells washed and theﬁlter
membrane excised from the insert. Cells were mounted on a slide using
1,4-diazabicyclo[2.2.2]octane (DABCO) (1% diluted in 9:1 glycerol:PBS)
and covered with a glass cover slip. Confocal imaging was carried out
using a Leica SP2 CLSM-Micro4 confocal microscope.
2.9. Clathrin and caveolae inhibition studies
Filipin (5 μg/ml) and chlorpromazine (10 μg/ml) were used as
inhibitors of speciﬁc endocytic pathways (caveolae and clathrin,
respectively). Cells were treated with the inhibitors, in HBSS/
HEPES, for 1 h at 37 °C prior to the addition of particles [23].
Unmodiﬁed and B12-conjugated nanoparticles (as IF composites and
without IF) were applied in HBSS/HEPES (400 μg/ml) containing one
of the above inhibitors and incubated for 3 h. Control experiments
with known ligands for the clathrin- and caveolae- mediated pathways
(FITC-transferrin at 100 μg/ml and cholera toxin-B-subunit at 5 μg/ml,
respectively) were carried out as described previously [18]. To assess
the trafﬁcking route of soluble vitamin B12 and compare with that of
B12-bearing nanoparticles, vitamin B12 (1 mg/ml), in the presence of
IF, was also applied in conjunction with the same inhibitors and cell
uptake and transport determined via UV-absorbance at 350 nm.
2.10. Statistical analysis
All experiments were carried out using triplicate samples and were
repeated three times. One way analysis of variance (ANOVA) followed
by Bonferroni post-hoc test was applied for comparison of group
means of three or more groups, whilst Student's t-test was used for
comparison of two groups. Data shown as the mean ± SD of three
different experiments. p values of b0.05 were considered statistically
signiﬁcant. *, ** and *** denote p b 0.05, p b 0.01 and p b 0.001, respec-
tively, whilst ‘ns’ indicates non-signiﬁcant.
3. Results
3.1. Cubilin and TCII receptor expression in Calu-3 cells
3.1.1. mRNA expression
PCR and gel electrophoresis analysis of differentiated Calu-3 cells
(cultured on permeable supports as polarised layers), conducted to de-
termine mRNA expression of cubilin (human CUBN gene) and the gene
encoding TCII receptor (CD320), is shown in Fig. 1a. The data conﬁrm
the expression of both cubilin (i) and TCII receptor (ii) (cDNA ampliﬁca-
tion products of 602 and 343 bp, respectively). A secondary fragment
(~260 bp) with weak intensity, in addition to the band detected at
343 bp (for CD320), was also detected, which possibly results from an
alternatively spliced transcript variant encoding a different isoform.
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The expression of cubilin, TCII receptor and TCII protein, at protein
level, is demonstrated by immunostaining. This is shown in Fig. 1b. Con-
sidering the expression of cubilin, ﬂuorescence signal was detected and
appears distributed across the depth of the cell layer in the sample treated
with both primary and secondary antibodies (Fig. 1b i), implying a
non-polar receptor distribution. Fluorescence was not apparent in the
control experiment where treatment with the primary antibody was
omitted (Fig. 1b ii). Immunostaining for TCII receptor reveals intense
staining, indicating its expression in Calu-3 cells (Fig. 1b iii). No ﬂuores-
cencewas detected in the control experiment (i.e. treatmentwith the sec-
ondary antibody only, Fig. 1b iv). Immunostaining for TCII protein, a
carrier protein involved in the binding and transport of B12 out of the
enterocytes in vivo, indicates its presence in Calu-3 cells (Fig. 1b v), whilst
ﬂuorescence signal was largely absent in the relevant control experiment
(Fig. 1b vi).
3.2. Characterisation of B12-conjugated nanoparticles
The characterisation of amino-derivatized B12 by means of
nuclear magnetic resonance (NMR), mass spectrometry (MS), and
high-performance liquid chromatography (HPLC), as well as characteri-
sation of conjugated nanoparticles is shown in our recently published
work, which employed the same B12-modiﬁed nanoparticles [18]. Brief-
ly, nanoparticle size and surface charge before and after B12 conjugation
were determined by dynamic light scattering and zeta potential mea-
surements, demonstrating a change in both parameters post-B12 conju-
gation. The presence of B12 on the surface of conjugated polystyrene
nanoparticles was conﬁrmed by ﬂuorescence quenching, based on the
ﬂuorescence quenching ability of B12, which was previously demon-
strated in work by our group [18] and others [24,25]. This is shown by
experiments determining the ﬂuorescence of physical mixtures of
nanoparticles and B12, as well as B12-conjugated nanoparticles before
and after dialysis (performed to separate soluble B12 from unconjugated
nanoparticles). The data shown in Supporting information, Fig. S2,
demonstrates that B12-conjugated nanoparticles displayed a lower
ﬂuorescence intensity compared to unmodiﬁed nanoparticles and that
ﬂuorescence remained unchanged following dialysis (unlike physical
mixtures of soluble B12 and nanoparticles).
3.3. Cell uptake and transport of B12-conjugated nanoparticles
Fig. 2a provides a comparison of cell uptake of B12-conjugated
nanoparticles with unmodiﬁed counterparts of the same pre-
conjugation diameter. Following a three-hour incubation period,
the uptake of B12-conjugated nanoparticles by Calu-3 cells was
larger compared to unmodiﬁed nanoparticles. This trend applied
to both 50 nm (45 μg versus 31 μg for B12-conjugated and unmodiﬁed
nanoparticles, respectively) and 100 nm systems (15 μg versus 8 μg).
Testing the effect of intrinsic factor (IF) on the cell uptake of
B12-conjugated nanoparticles, Fig. 2a also shows that the presence of
IF in the system modestly promoted the uptake of B12-nanoparticles,
with the effect being marginally larger for 50 nm nanoparticles (1.25-
fold increase), compared to 100 nm nanoparticles (1.16-fold).
Mirroring the cell uptake data, the results showing nanoparticle
transport across polarised cells (Fig. 2b and c) revealed that
B12-conjugated nanoparticles traversed Calu-3 cell layers more efﬁcient-
ly than the unmodiﬁed counterparts, regardless of their size. The differ-
ence in transport between B12-bearing and unmodiﬁed nanoparticles
of the samenominal diameterwas notable: 0.240–0.292 ng/s/cm2 versus
0.077 ng/s/cm2 (up to 3.8-fold difference) and 0.98–1.263 ng/s/cm2
versus 0.047 ng/s/cm2 (up to 27-fold difference) for 50 nm and
100 nm nanoparticles, respectively. Transport of nanoparticles over 3 h
was somewhat lower in the absence of IF and the level of transport
was signiﬁcantly larger for 100 nm, relative to 50 nm nanoparticles,
with or without the presence of IF in the system. Cumulative apical-to-
basolateral transport of 100 nm nanoparticles at the end of the three-
hour exposure reached high levels of approximately 15 μg — a similar
level to the amount nanoparticles found intracellularly at this time point.
a)
i 
b)
i  
iii
v 
ii 
iv
vi  
ii 
Fig. 1. Cubilin, TCII receptor and TCII protein expression in polarised Calu-3 cells on day 21
of culture. a) mRNA expression of (i) cubilin (lanes 1 & 2) and (ii) TCII receptor (CD320)
(lanes 3 & 4). *Ctrl denotes PCR product obtained fromCaco-2 cellmonolayer. b) Immuno-
staining for cubilin (i–ii), TCII receptor (iii–iv) and TCII (v–vi). i) Red signal from
Rhodamine-labelled goat, anti-rabbit IgG antibody to rabbit anti-human cubilin H-300pri-
mary antibody. ii) Control experiment where cells were treated with Rhodamine-labelled
goat, anti-rabbit IgG only (i.e. treatment with the primary antibody was omitted). iii) Cells
immunostained for TCII receptor with rabbit, anti-human CD320 antibody and chicken,
anti-rabbit Alexa Fluor 488 secondary antibody. iv) Control experiment showing cells
treatedwith chicken, anti-rabbit Alexa Fluor 488 secondary antibody only. v) Cells immu-
nostained for TCII with rabbit, anti-human TCII H-260 and Rhodamine-labelled goat, anti-
rabbit IgG secondary antibody. vi) Control experiment in which cells were treated with
Rhodamine-labelled goat, anti-rabbit IgG only. Blue = cell nuclei stained with Hoechst.
Micrographs shown as overlay images showing both blue and red or blue and green
channels.
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3.4. Cell uptake of B12-conjugated nanoparticles: confocal microscopy
Confocal micrographs of polarised Calu-3 cells following incubation
with unmodiﬁed and B12-conjugated nanoparticles are presented in
Supporting information, Fig. S3a and b, respectively. In both conditions
themicrographs clearly show the presence of nanoparticle-emitting red
ﬂuorescence signalwithin the cells. Imaging in sections across the depth
of the cells shows the distribution of ﬂuorescence across the vertical
plane of the cell layers (depicted on the right and bottom sides of
the images), indicating nanoparticle presence deep within the cells,
rather than simple association with the cell membranes. It must be
noted that nanoparticle ﬂuorescence signal was more apparent for
unmodiﬁed nanoparticles compared to B12-conjugated nanoparticles
(imaged under the same confocal microscopy settings), though quanti-
tation of nanoparticle uptake demonstrated that the latter were taken
up by the cells more efﬁciently (Supporting information, Fig. S3a).
This is probably due to the prominent ﬂuorescence quenching capacity
of B12, as shown in Supporting information, Fig. S2.
3.5. Immunostaining for clathrin and caveolin-1
Calu-3 expression of key proteins relevant in two speciﬁc endocytic
pathways, namely clathrin (implicated in the trafﬁcking of the soluble
B12-IF complex) and caveolae pathways, was conﬁrmed by immuno-
staining. The data shown in Fig. 3 conﬁrmed the expression of these pro-
teins (clathrin and caveolin-1 in Fig. 3a and b, respectively) in the
airway model, as shown by the presence of ﬂuorescence signal in cell
samples treated with the relevant antibodies and lack of ﬂuorescence
in control samples where exposure to the secondary, ﬂuorescently-
tagged antibody was omitted. This is in agreement with previously
reported ﬁndings [26].
3.6. Epithelial trafﬁcking of soluble B12
Studies assessing the uptake and transport route of soluble B12
in airway epithelial cell layers were undertaken using endocytic
pathway-speciﬁc inhibitors, chlorpromazine and ﬁlipin. Speciﬁc inhibi-
tion of cell uptake pathways by these agents in Calu-3 cells was exam-
ined by assessing their effect on the uptake and transport of clathrin
and caveolae pathway-selective ligands, transferrin [27,28] and cholera
toxin B-subunit [29,30], respectively (Supplementary information,
Fig. S4). Cell uptake of FITC-transferrin in the presence of chlorproma-
zine was inhibited by approximately 2-fold (Fig. S4a), whilst ﬁlipin
induced a dramatic 21-fold decrease in the cellular internalisation of
cholera toxin B-subunit (Fig. S4b).
Considering the effect of endocytosis inhibitors on cell uptake and
transepithelial transport of soluble B12, Fig. 4 shows that both agents
had an impact on cell uptake (Fig. 4a), with ﬁlipin causing a modest re-
duction in cell uptake (by approximately 25%) and chlorpromazine hav-
ing amarkedlymore prominent effectwith a 95% suppression of soluble
B12uptake. A similar observationwas noted in transport studies: soluble
B12 transport across ﬁlipin-treated cells was reduced compared to
untreated cells, with a notable inhibitory effect in the initial phases of
the experiment (Fig. 4b), which latter recovered. Overall transport inhi-
bition by ﬁlipin, as determined from ﬂux values (Fig. 4c), amounted to
23%. Chlorpromazine on the other hand induced a high level of trans-
port inhibition (with a reduction in ﬂux by 94%).
3.7. Airway epithelial cell trafﬁcking of B12 conjugated nanoparticles
Cell uptake of 100 nm B12-nanoparticles was affected by both
chlorpromazine and ﬁlipin treatment, producing a statistically signiﬁ-
cant reduction in the extent of nanoparticle uptake (Fig. 5a). Treatment
with chlorpromazine induced a 3.4-fold decrease in nanoparticle
internalisation (p = 0.002), whereas application of ﬁlipin caused a
2.1-fold reduction in the extent of uptake (p = 0.004). Transport data
also illustrates the same phenomenon: after 3 h, cumulative amounts
of B12-nanoparticles on the basal side in untreated cells reached
~17 μg, versus 0.9 and 0.4 μg, in ﬁlipin- and chlorpromazine-treated
cells, respectively (Fig. 5b). Nanoparticle ﬂux across the airway epitheli-
umwas reduced dramatically by 96.9% and 97.4% due to chlorpromazine
and ﬁlipin treatment, respectively (Fig. 5c). These trends therefore
suggest that cell uptake and transport of B12-conjugated nanoparticles
was noticeably affected by the inhibition of either clathrin or caveolae-
mediated routes in airway Calu-3 cells.
4. Discussion
Non-invasive delivery of biotherapeutics for a systemic effect is
potentially feasible with administration via the mucosal surfaces.
However, the epithelium presents an almost impenetrable barrier to
the movement of macromolecular therapeutics into the systemic circu-
lation. Natural epithelial transport pathways involved in the absorption
of nutrients (e.g. vitamin B12 and folate) or regulation of immune re-
sponses (IgG/FcRn)have therefore been considered as potentially useful
targets to ‘hijack’ for delivery of therapeutics and/or therapeutic carriers
such as nanoparticles. However, not many known pathways are able to
efﬁciently transport material transepithelially (i.e. transfer cargo across
the cells, as opposed to merely internalising). To this end, the vitamin
B12 absorption pathway has been relatively well investigated for its po-
tential to ‘carry’ therapeutic biomolecules, as well as nanoparticles as
drug carriers, transepithelially. However, these studies have beenmain-
ly conducted in Caco-2 cells, as an in vitromodel of the intestinal epithe-
lium, which is an obvious selection based on physiological absorption of
dietary B12.
Information on the presence of the transcytotic machinery involved
in transepithelial trafﬁcking of B12 in the bronchial epithelium is, to our
knowledge, not available, although the expression of cubilin in alveolar
A549 cell line has recently been reported [19]. Therefore, a combination
of molecular biology and immunostaining techniques was used to de-
termine the presence of the relevant components at mRNA and protein
level in airway Calu-3 cells. mRNA expression of cubilin and TCII recep-
tor was analysed using PCR and gel electrophoresis. The data demon-
strated the expression of both components (Fig. 1) in Calu-3 cells, as
in Caco-2 cells, whichwere used as a control as the expression of cubilin
and TCII receptor in these cells is widely acknowledged [31–33]. The
expression of cubilin, TCII receptor and TCII protein in Calu-3 cells was
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Fig. 2. Cell uptake and transport of B12-conjugated nanoparticles in Calu-3 layers: a) Cell
uptake of B12-conjugated nanoparticles (50 nmand 100 nm) in the presence and absence
of intrinsic factor (IF) and unmodiﬁed nanoparticles. b) Transport of B12-conjugated
nanoparticles (50 and 100 nm) in the presence and absence of IF, and unmodiﬁed
nanoparticles. c) Nanoparticle transport ﬂux. Data represents the mean ± SD.
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also conﬁrmed at protein level using immunoﬂuorescence (Fig. 1b). The
expression of these constituents of the B12 transport system at gene and
protein level therefore indicates that vitamin B12 cell trafﬁcking activity
may operate in the airway epithelium.
Cubilin has been previously shown tobe expressed in the renal prox-
imal tubule and the visceral yolk sac [34], the placental cytotrophoblast
and possibly other tissues such as thymus [35], in addition to the small
intestinal epithelium.Whilst its expression in the renal proximal tubule,
which exhibits a very extensive apical endocytic apparatus involved in
the re-absorption and conservation of important molecules (such as
vitamin B12) ﬁltered in the glomeruli, is perhaps unsurprising, cubilin
functionality in the airway epithelial cells is unclear. However, it
presumably plays a physiological role in the uptake (rather than
transepithelial transport) of B12 as an essential agent in key metabolic
processes, similarly to the expression of folate receptor (another
vitamin B subtype) in airway epithelial cells [21].
Following the demonstration that Calu-3 cells express vitamin B12
receptor, TCII receptor and TCII protein, we next determined the pres-
ence of other structural cell components participating in the process
of endocytosis or transcytosis. This was deemed necessary as whilst
the expression of cubilin and TCII receptor is required for the ligand–
receptor binding stage of endocytosis, other components of the cell ma-
chinery are responsible for subsequent trafﬁcking of B12. Further work
therefore determined whether Calu-3 cells express relevant key pro-
teins involved in two speciﬁc endocytic pathways, including the essen-
tial components of clathrin-coated pits, implicated in the internalisation
of the soluble B12-IF complex, as well as caveolae (caveolin-1) as another
route for material internalisation. The work conﬁrmed the expression of
these proteins by airway Calu-3 cells (Fig. 3), which was also shown in
a previous study [26].
Amino derivatization of B12 and characterization of B12-bearing
nanoparticles in terms of surface modiﬁcation, size and charge, were
reported in our recent work [18]. These nanoparticles, used as model
therapeutic nanocarriers or nanomedicines, demonstrated interesting
cell uptake and transport behaviours. B12-conjugated nanoparticles of
50 nm and 100 nm (nominal diameter) demonstrated improved cell
uptake and transport across the cell layers, as compared to unmodiﬁed
nanoparticles, with IF modestly inﬂuencing the extent of cell uptake
(Fig. 2). Fluorescently-labelled B12-decorated nanoparticles were also
clearly observed within Calu-3 cells following imaging by confocal
microscopy (Supporting information, Fig. S3). In addition to demon-
strating higher cell uptake, B12-conjugated nanoparticles transported
across the cell layers notably more efﬁciently than unmodiﬁed
nanoparticles, irrespective of their size. In the absence of IF, nanoparticle
a) 
b) 
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i
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Fig. 3. Expression of select endocytic components by immunohistochemistry in Calu-3
cells (as polarised layers). a) Expression of clathrin, as demonstrated by cell incubation
with rabbit anti-clathrin primary antibody and goat, anti-rabbit IgG-FITC (i), and control
monolayer treated with the secondary, goat, anti-rabbit IgG-FITC only (ii). b) Expression
of caveolin-1, shown by treating cells with anti-human caveolin 1H-97, followed by
goat, anti-rabbit IgG-Rhodamine (i), and control monolayer, incubated with goat, anti-
rabbit IgG-Rhodamine only (ii). Cell nuclei were labelled with Hoechst 33342 (blue) in
all cases. Immunostaining for all components was performed on day 21 of Transwell
culture.
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Fig. 4. Effect of endocytic pathway-speciﬁc inhibitors on cell uptake and transport of
soluble vitamin B12 in Calu-3 cell layers. a) Effect of chlorpromazine and ﬁlipin on cell up-
take of B12. b) Effect of chlorpromazine and ﬁlipin on transport of B12 across Calu-3 layers.
c) Soluble vitamin B12 transport ﬂux. B12was applied in combination with IF and quanti-
ﬁed by UVAbs (350 nm). Data represents the mean ± SD.
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transport was somewhat reduced, indicating that IF plays a role (albeit
minor) in the trafﬁcking of B12-bearing nanoparticles. It is interesting
to note that the transport of 100 nm nanoparticles was signiﬁcantly
larger relative to 50 nm nanoparticle, despite 50 nm B12-conjugated
nanoparticles being internalised by the cells to a greater extent.
In vivo, native soluble B12 binds to IF and the B12-IF complex in turn
binds to the cubilin receptor situated in the apical brush border mem-
brane of the ileal mucosa [36]. Association of cubilin with megalin, a
member of the LDL receptor-related family of endocytic receptors,
[37,38] leads to internalisation of the entire cubilin-IF-B12 complex via
clathrin-coated vesicles [39]. Our recent work showed that in intestinal
Caco-2 cells soluble vitamin B12 internalises via clathrin-mediated en-
docytosis [18]. The mechanism of cell entry of soluble B12 in airway
Calu-3 cells was also probed with chlorpromazine and ﬁlipin as cell
trafﬁcking inhibitors of clathrin- and caveolae-mediated endocytosis,
respectively [23,29,30]. Soluble B12 internalisation and transport were
signiﬁcantly suppressed by the action of chlorpromazine. The caveolae
inhibitor, ﬁlipin, displayed a modest effect on these phenomena
(Fig. 4), with a 25% reduction in uptake and some inﬂuence in the pat-
tern of transport over the three-hour experiment. The data therefore
suggests that vitamin B12 is trafﬁcked predominantly via a clathrin-
mediated route in airway Calu-3 cells, which is in accord with previous
reports related to other epithelial tissue [40,41], as well as our observa-
tions with intestinal Caco-2 cells [18]. However, whilst in intestinal
Caco-2 cells caveolae played no role in the internalisation of soluble
B12, the data suggests that, to a degree, there might be an element of
cross-talk between the two pathways in airway Calu-3 cells. Further-
more, paracellular transport of soluble vitamin B12 cannot be ruled
out, as suggested for other vitamin B family sub-types [42], which may
partly contribute to the observed high level of permeability across the
epithelial cells. Similar levels of transepithelial transport have also
been reported in intestinal Caco-2 monolayers in studies using compar-
ative (higher than physiological) doses of vitamin B12 [43,44].
The cell internalisation route of B12-conjugated nanoparticles was
probed by the same endocytosis inhibitors used in experiments
establishing soluble B12 trafﬁcking. The data shows that cell uptake
and transport of B12-bearing nanoparticles was inhibited by both chlor-
promazine and ﬁlipin (Fig. 5), implying that these nanoparticles are
trafﬁcked by both clathrin-mediated and caveolae-mediated pathways.
Interestingly, this ﬁnding is notably different to the trends observed for
Caco-2 cells, where transport of 50 nm B12-conjugated nanoparticles
takes place by a route that predominantly involves caveolae [18]. This
work therefore not only identiﬁes the presence of biological machinery
of vitamin B12 trafﬁcking in airway epithelial cells but also demonstrates
B12-mediated nanoparticle transport into and across the airway epithe-
lium cells — a previously unreported observation. The trafﬁcking of
B12 bioconjugated nanoparticles in the Calu-3 airway model occurs
through different endocytic pathways compared to both soluble B12
and unmodiﬁed nanoparticles. Demonstration that cell uptake and sys-
temic entry of nano-sizedmodel drug carriers can occur through the air-
way epithelium via the vitamin B12 transport system is of potential
signiﬁcant impact in the ﬁeld of nanomedicine and warrants further re-
search. However, it must be noted that our study was based on a single
cell line. The ﬁndings will of course have to be conﬁrmed in the future
using other airway cell types and, importantly, in vivo.
A potential limitation to nanocarrier delivery across the airway
mucosa is the presence of mucus. The viscoelastic and adhesive
mucus layer that lines the bronchial epithelium presents a barrier
to transmucosal movement of nanoparticles and this should be con-
sidered when designing nanocarrier delivery systems for systemic deliv-
ery through the airways. Particlemobility inmucus is dependent on their
surface properties, whereby anionic particles diffusemore efﬁciently (up
to 20–30 times faster) than cationic particles [45] and surface PEGylation
remarkably enhances nanoparticle movement in mucus [46,47]. Whilst
our work shows the expression, functionality and nanoparticle transport
capacity of the vitamin B12 pathway in a bronchial epithelial cell line, in-
terestingly, cubilin expression has also recently been demonstrated in
human alveolar A549 cells [19]. Assuming that this biological transport
pathway is also functional in the alveolar epithelium, it is possible that
the deep lung region also contributes to the absorption of B12 decorated
nanocarriers, which is an interesting prospect considering the enormous
surface area of the alveolar epithelium and the lack of mucus barrier in
this region. This may be examined in the future in vitro using primary
human alveolar epithelial cells [48,49], or in animal studies.
5. Conclusion
The work investigated the presence of the vitamin B12 transport
system and its capacity to transport nanoparticles in polarised airway
Calu-3 cells. The expression of B12 transcytosis component proteins in
Calu-3 cells was shown at mRNA and protein level. B12-decorated
nanoparticles displayed a larger capacity to enter and transport across
airway epithelial cell layers (with or without the presence of IF) com-
pared to unmodiﬁed nanoparticles. Whilst soluble B12was found to in-
ternalise into Calu-3 cells predominantly by a clathrin-mediated route,
cell uptake and transport of B12-conjugated nanoparticles were dramat-
ically affected by both clathrin and caveolae inhibition, suggesting a
different B12 intracellular trafﬁcking as a result of its mobilization
on nanoparticle surface. The work therefore reveals a previously
unexplored route of nanoparticle cell entry and transepithelial transport
across the airway epithelium,with a potentially important impact in the
area of mucosal delivery of nanomedicines.
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Appendix A. Supplementary data
Modiﬁcation of nanoparticleswith B12 (shown by ﬂuorescence char-
acterization), the inﬂuence of nanoparticles on cell layer TEER, cell up-
take of nanoparticles and the effect of chemical inhibitors on cell
uptake of pathway selective ligands in airway Calu-3 layers are shown
as supplementary material. Supplementary data to this article can be
found online at http://dx.doi.org/10.1016/j.jconrel.2013.08.028.
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